It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 6.5% in that time frame, outperforming the S&P 500. But investors have to be ...

ARK’s activity in the biotech sector was highlighted by the purchase of 50,728 shares of Recursion Pharmaceuticals Inc (RXRX) through its ARKK ETF, totaling $2,090,030. Additionally, ARK acquired ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...

Recursion Pharmaceuticals merged with Exscientia, another AI-driven drug discovery company, positioning itself as a potential biotech innovator The company has partnerships with major pharmaceutical ...

Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...

The Python Software Foundation has rejected a $1.5 million government grant because of anti-DEI requirements imposed by the Trump administration, the nonprofit said in a blog post yesterday. The grant ...

Already using NumPy, Pandas, and Scikit-learn? Here are seven more powerful data wrangling tools that deserve a place in your toolkit. Python’s rich ecosystem of data science tools is a big draw for ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...